Falk Gastro Info 3/2017

Video

Video course abdominal ultrasound

Examination of the mediastinum: Supraaortal region

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Casanova MJ, Am J Gastroenterol. 2017;112(1):120–31

Prognosis of inflammatory bowel disease after Anti-TNF discontinuation: Results of a large retrospective cohort study confirm that approx. half of patients relapse within 2 years, but retreatment with the same anti-TNF drug appears to be effective and safe

Link to text

Text:

Vermeire S, Lancet. 2017;389(10066):266–75

Efficacy of the JAK1 inhibitor filgotinib in Crohn’s disease: Results from a phase 2 trial (FITZROY) indicate that filgotinib induces clinical remission in significantly more patients than placebo with an acceptable safety profile.

Link to text

Text:

Wilcox MH, N Engl J Med. 2017;376(4):305–17

Novel therapeutic approach against Clostridium difficile infection: Two phase III trials report that Bezlotoxumab, a monoclonal antibody targeting the bacterial toxin B, is associated with substantially lower rates of recurrent infection than placebo with a similar safety profile.

Link to text

Liver Biliary Tracts

Text:

Wranke A et al, Hepatology. 2017;65(2):414–25

Hepatitis D: Interferon-α-based antiviral therapy is associated with a reduced risk of complications such as ascites, encephalopathy, variceal bleeding, hepatocellular carcinoma, liver transplantation, and liver-related death. Durable negativity of hepatitis D virus RNA is a valid surrogate endpoint in hepatitis D therapy.

Link to text

Text:

Allard N et al, J Viral Hepat. 2017;24(1):53–8

Hepatitis B: Adherence to antiviral therapy for hepatitis B is influenced by patient characteristics (poor adherence in patients aged < 35 years) and quality of outpatient care (poor adherence with treatment by multiple doctors within short time period).

Link to text

Text:

Bacq Y et al, Dig Liver Dis. 2017;49(1):63–9

Intrahepatic cholestasis of pregnancy: A current observational study including 98 patients impressively demonstrates the beneficial effect of ursodeoxycholic acid on pruritus, ALT levels, and bile acid concentrations and supports the use of ursodeoxycholic acid as first-line therapy in intrahepatic cholestasis of pregnancy.

Link to text

Oesophagus Stomach Duodenum

Text:

Chan FKL, Gastroenterology. 2017;152(1):105–10.e1

Risk of upper gastrointestinal bleeding or ulcers: Proton-pump inhibitors and H2-receptor antagonists have similar efficacy of risk reduction in high-risk patients treated with low-dose aspirin.

Link to text

Text:

Ludvigsson JF, Gastroenterology. 2017;152(3):554–63.e9

Outcome of pregnancies for women undergoing endoscopy while being pregnant: Endoscopy is associated with increased risk of preterm birth or small for gestational age, but these risks are small and likely due to individual risk factors and activity of underlying disease.

Link to text

Text:

Targownik LE, Am J Gastroenterol. 2017;112(1):95–101

Suspected side effects of proton-pump inhibitor (PPI) therapy: Long-term PPI use is not associated with changes in bone strength and structure.

Link to text

Pancreas

Text:

Choi JH, Clin Gastroenterol Hepatol. 2017;15(1):86–92.e1

Prophylaxis of post-ERCP-pancreatitis (PEP): Vigorous periprocedural hydration with lactated Ringer’s solution substantially reduces the risk of PEP.

Link to text

International Symposia and Workshops

Symposium 206

From the New and Complex Concepts to the Real Patient: Science and Clinic in IBD

March 31 ñ April 1, 2017, Madrid, Spain

Meli· Castilla Hotel, Calle del Capit·n Haya, 43, 28020 Madrid, Spain

Fully booked

Program

Registration

Online registration

Symposium 207

Gut Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions